Acrivon Therapeutics Inc (ACRV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.13+3.40%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Acrivon is making progress in cancer drug trials with 44% response rate. The company has about $119 million cash to fund operations into Q2 2027. Operating losses are improving from -$25.1 million to -$19.9 million. Cost control and clinical progress support future value.
Acrivon still loses money and has no revenue. Cash burn remains high. Clinical progress is uncertain and could fail.
The market has no clear price or growth expectations due to lack of revenue and earnings. Our view is cautious given ongoing losses and early clinical stage.
Breaks if: cash reserves fall below $118.6 million before Q2 2027
Maintain sufficient cash, cash equivalents, and investments to fund operating expenses and capital expenditures into the second quarter of 2027.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. ACRV is focused on advancing its clinical programs while managing significant operating losses and cash burn.
The market appears to have priced in the current challenges of being loss-making and the potential for further guidance cuts. There is a cautious sentiment given the elevated risk factors and the mixed recent performance compared to peers.
Management is focused on advancing clinical trials and maintaining cash runway, but the company continues to experience operating losses. Recent earnings beats have provided some positive momentum, although the overall financial performance remains neutral.
The long-term thesis hinges on the outcomes of clinical trials and the ability to manage cash burn effectively. Additionally, broader sector performance and macroeconomic conditions, such as employment trends, could significantly impact ACRV's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats affecting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: ORR falls below 39% overall or below 44% in ≤2 prior therapy patients
Progress clinical trials and registrational-intent studies for key drug candidates including ACR-368.
Breaks if: operating loss worsens beyond -$19.9 million or cash burn beyond -$12.3 million
Control operating expenses and cash burn while advancing clinical programs to extend financial runway.
Stated as a priority in 2 of last 2 quarters. Operating losses improved modestly from -$21.0 million in 2025-Q2 to -$18.0 million in 2026-Q2, driven by reduced R&D and G&A expenses. Cash from operations remains negative, reflecting ongoing burn, but expense control efforts show limited progress consistent with management's statements.
“R&D expenses $13.8M vs $16.2M prior year; G&A expenses $4.8M vs $6.5M prior year, reflecting cost reductions.”
“R&D expenses $15.2M vs $15.4M prior year; G&A expenses $4.7M vs $6.2M prior year, driven by lower employee-related costs.”
In the next 1 to 3 years, ACRV's success will depend on its clinical advancements and market conditions. Not investment advice.